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Thoracic Endovascular Aortic Repair (TEVAR) is associated with
reduced perioperative mortality and morbidity compared to
conventional surgery, but also with a number of post-operative
early and late complications, which may require re-intervention,
either surgical or endovascular.1e4 For that reason, TEVAR
patients need to be followed with imaging studies. In most of the
centers performing TEVAR strict imaging follow-up protocols have
been adopted. The latter consist most commonly of repeated
computed tomography angiography (CTA) or magnetic resonance
angiography (MRA) controls at 1, 6 and 12 months postoperatively
and yearly thereafter.4,5 Although it is clear that a number of TEVAR
patients will beneﬁt from such protocoled surveillance regimens, it
is uncertain whether all TEVAR patients need annual and lifelong
imaging follow-up. Such a protocoled surveillance regimen may be
unnecessary for many patients. In addition, the health risks and
ﬁnancial costs of annual CTA/MRA must be taken into account.
Herein, we present reasons why not all TEVAR patients need annual
CTA/MRA follow-up lifelong.
Need for follow-up with regard to pathology treated by TEVAR
TEVAR was initially introduced as a minimal invasive treatment
option for thoracic aortic aneurysms. Since then, several additional
pathologies of the thoracic aorta have been treated by TEVAR.
Despite the fact that most of these pathologies are outside the
manufacturer’s Instructions for Use (IFU), TEVAR has been applied
with success in traumatic transection, pseudoaneurysm, dissection,
perforating ulcer, coarctation and intramural hematoma.6e10 Re-
intervention rates in these pathologies compared to TEVAR for
aneurysmal thoracic disease were reported to be lower.7 Impor-
tantly, many of the above mentioned pathologies do not represent
an evolving disease process, as in the case of degenerative thoracic
aortic aneurysms, but a stable condition or post-traumatic injury
requiring treatment. After technically successful intervention with
good short- and mid-term documented outcome, further annual
CTA/MRAmay not be mandatory. A young 23-year-old male treated* Corresponding author. Tel.: þ49 9113982650.
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http://dx.doi.org/10.1016/j.ejvs.2012.09.014successfully with a modern ﬂexible thoracic stent-graft (e.g., Zenith
Tx2 Proform, Cook Inc, Bloomington, IN, USA) for traumatic aortic
transection with 1-year unremarkable follow-up result on CTA
could be followed by a yearly chest X-ray or a CTA every two to
three years (Fig. 1). Similarly, a 76-year-old male who was treated
for intramural hematoma with a cTAG graft (W.L.Gore &Associates,
Flagstaff, AZ, USA) does not need a strict surveillance if 3-years
follow-up CTA demonstrates an unremarkable and stable situa-
tion (Fig. 2). A 37-year-old man who was treated by TEVAR for
a pseudo-aneurysm in the descending thoracic aorta after several
open procedures including an extra-anatomic bypass from
ascending-to-descending aorta, does not need yearly control CTA/
MRA when the 8-year follow-up result shows exactly the same
outcome as the control angiography after the initial procedure
(Fig. 3a and b). With many more examples like these at hand, it
seems very reasonable to individualize follow-up according to the
primary TEVAR indication and to the result after treatment.Aim of follow-up after TEVAR
Imaging follow-up after TEVAR aims to diagnose potential
adverse events and complications such as device migration,
disconnection or endoleak, which may require further treatment.
The latter is important and has to be taken into account in order to
justify extensive follow-up imaging studies including CTA or MRA.
In modern medicine, more and more protocols are introduced.
These protocols do serve safety and quality purposes, both for the
patient and for the doctor (e.g., protocols in polytraumatized
patients or in anesthesiology), but undoubtedly lead to over
consumption. The clinical touch seems lost inmany areas in favor of
protocoled medicine: polytraumatized patients are submitted to
extensive imaging too quickly with clearly less focus on anamnesis,
clinical examination, and clinical differential diagnosis; anesthesi-
ology by the protocol is requesting extensive pre-operative inves-
tigations that will most likely not beneﬁt the patient but protect the
doctor from later liability issues. The increased ﬁnancial costs of
such overrated protocols must be taken into account, as well as the
potential harm of some additional investigations.11
There is no clear evidence to support a strict follow-up protocol
after TEVAR. The recommendation to do so was derived empirically
from early multicenter studies using ﬁrst generation devices, withed by Elsevier Ltd. All rights reserved.
Figure 1. CTA reconstruction at 1 year after TEVAR with a Zenith TX2 proform for an
acute aortic transaction in a 23-year-old male.
Figure 2. (a) CTA showing pre-operative sagittal view of perforating ulcer in a 76-y
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evaluate a new technique. This is not the case anymore, with TEVAR
being in its second decade. Devices and techniques have evolved
and indications broadened, as mentioned above. This calls for
a speciﬁc and individually tailored follow-up approach. Neverthe-
less, longer term quality data on each indication are required, but
this should be achieved within strict study protocols. Potential pre-
operative risk (pathology treated, anatomical features) factors
should be identiﬁed to deﬁne which patients should have a more
strict follow-up regimen.Health- and ﬁnancial costs of a CTA/MRA follow-up protocol
Several studies have demonstrated a decline in renal function in
EVAR patients, related to the cumulative contrast load from
repeated CTAs.12,13 MRAwas initially thought not to be nephrotoxic,
but many studies have showed that MRAwith single or double dose
of Gadolium contrast agents carries a nephrotoxic effect.14e16
The potential carcinogenic effects of the cumulative radiation
exposure from CTA are also becoming more evident.17 A TEVAR
procedure including one pre-operative CTA, three follow-up CTA’s
for the ﬁrst year, with a yearly evaluation thereafter results in a high
radiation exposure, with a lifetime risk increase of more than 2.7%
in radiation-induced leukemia and solid-tumour cancer within 15
years.18 Younger patients, smokers and women are carrying an
even higher risk.16 Three alternatives have been advocated to
reduce radiation exposure: i) reduction of the effective doseear-old, treated with a cTAG thoracic stent-graft, (b) same at 3-year follow-up.
Figure 3. (a) Postoperative angiography, (b) 8-year postoperative CTA after TEVAR for pseudo-aneurysm in a 37-year-old patient. This patient had been treated by open means for
coarctation including an extra-anastomotic bypass from ascending-to-descending aorta.
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requested, or iii) replacement of CTA with alternative modes of
imaging/assessment.19
Finally, the cost aspect must not be underestimated. With EVAR,
several studies have demonstrated that a less intensive surveillance
protocol with selective use of CTA, duplex ultrasound and abdom-
inal X-ray instead of standard annual follow-upwith CTA is cheaper
and could make EVAR cost-effective compared to open repair.20e23
In TEVAR, duplex ultrasound is not applicable, but X-ray can still
provide valuable information on migration and disconnection.
Applying a selective CTA follow-up scheme would make TEVAR
more attractive in terms of cost-effectiveness, given that imaging
costs constitute 30%e35% of the total post-implant costs during the
5-year period after EVAR.11
Taking the above mentioned three arguments (nephrotoxicity,
radiation, cost) into consideration it seems sensible to reduce the
number of CTA/MRA after TEVAR, whenever medically justiﬁable.
Several options are available: use of non-contrast CT allows for
measurement of aneurysm sac diameter; plain radiography diag-
noses integrity of the device and migration; intravascular ultra-
sound (IVUS) can detect endoleaks; and intra-sac pressure
measurements could also play a role after TEVAR.24,25 Finally MRA
could replace CTA in stent-grafts without stainless steel.26
Conclusions
Not ALL TEVAR patients need to be followed by ANNUAL and
LIFELONG CTA/MRA. The latter should be used with caution, only to
detect complications that may require additional treatment.
Follow-up schemes, bothwith regard tomethod and timing, shouldbe tailored and later adapted to the different pathologies treated by
TEVAR, and according to the anatomical risk factors and the clinical
outcome. Alternative follow-up methods should also be re-
considered, in view of both health dangers and costs associated
with annual CTA/MRA.
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